Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Polycythemia Vera 4Treatment-Refractory Solid Tumors 2Meningioma 1Lymphoma, Follicular 1Leukemia, Myeloid, Acute 1

Interventions

Rituximab 26Cyclophosphamide 22Lenalidomide 21Prednisone 15Vincristine 13obinutuzumab 12Doxorubicin 12Magnetic Resonance Spectroscopy 10Bendamustine Hydrochloride 10Specimen Handling 8ibrutinib 7fludarabine 7Biopsy 7Peripheral Blood Stem Cell Transplantation 6pembrolizumab 5fludarabine phosphate 5Whole-Body Irradiation 5Radiotherapy 5zanubrutinib 4venetoclax 4tazemetostat 4R-CHOP protocol 4Prednisolone 4Mycophenolic Acid 3Etoposide 3Cyclosporine 3tisagenlecleucel 2polatuzumab vedotin 2orelabrutinib 2loncastuximab tesirine 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Lymphoma, Follicular × Hydroxyurea × 90 days × Clear all
NCT05020652 2026-06-02

A Clinical Trial of TQ05105 Tablets in the Treatment of Moderate and High Risk Myelofibrosis

Chia Tai Tianqing Pharmaceutical Group Co., Ltd.

Phase 2 Completed
107 enrolled
Lymphoid

Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡